Loading…
EA WORKS Limited Liability Company dba Trust Labs sold unapproved and misbranded drug products, including retatrutide, semaglutide, and tirzepatide, through its website coretrustlabs.com in violation of federal law. The company violated sections 505(a), 502(f)(1), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act by offering retatrutide as an unapproved new drug without proper FDA approval and adequate labeling, and by making false or misleading claims about compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb). The FDA's August 2025 inspection identified these products being introduced into interstate commerce without compliance with compounding exemptions or required regulatory pathways.